Atlas Trials

A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer

Clinical trial NCT01142778 · COMPLETED

Trial details

NCT number
NCT01142778
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2010-05-19
Primary completion
2017-12-13
Enrollment
152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.